Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508664-30-00

Enrollment

306

Registered

2025-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury

Brief summary

rate of complete renal recovery (success) assessed at day + 21 post-randomization. The complete renal recovery, (success) will be defined from the estimated glomerular filtration rate (eGFR): - if baseline eGFR is unknown; an eGFR >60ml/min (at day+21 according to the mention above) - if baseline eGFR is available; by the return to baseline eGFR +/- 3.

Interventions

DRUGNICOTINAMIDE

DRUGcellulose microcristalline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
rate of complete renal recovery (success) assessed at day + 21 post-randomization. The complete renal recovery, (success) will be defined from the estimated glomerular filtration rate (eGFR): - if baseline eGFR is unknown; an eGFR >60ml/min (at day+21 according to the mention above) - if baseline eGFR is available; by the return to baseline eGFR +/- 3.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026